Q-omics provides the consensus-scored MTUS1 profile across patient tissues and cancer cell-line models. MTUS1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MTUS1 is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, MTUS1 protein abundance shows 29,121 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRC, THCA, and LUAD as cancer lineages where MTUS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTUS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTUS1 survival associations across molecular data types. MTUS1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (8) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTUS1 RNA expression–survival associations across cancer types. High MTUS1 expression shows unfavorable associations in STAD, but favorable associations in KIRC, UVM, HNSC, LUAD and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MTUS1 RNA expression.
This table summarizes MTUS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 10. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MTUS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTUS1 shows lower tumor expression in COAD, KIRC, KIRP, BRCA and LUSC and higher tumor expression in THCA. The THCA box plot shows higher MTUS1 RNA expression in tumor versus normal tissue (log2 FC = +0.884, t-test p < 0.001).
This table shows molecular features associated with MTUS1 in patient tissues and cancer cell lines. In patient samples, MTUS1 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, MTUS1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Lymphoma.
